The new frontiers of DMT therapies

42:14
 
Share
 

Manage episode 304070460 series 2738732
By Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies: Algernon, Psilera, and Pharmadrug.

In this episode, we discuss:

  • DMT therapies for organ transplants, stroke patients and substance abuse disorders
  • Research supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targets
  • Being a private company vs. public company in psychedelics

NN-DMT
5-MeO-DMT
Bioavailability
DMT transdermal patch
Sigma-1
Donepezil
Dr. Rick Strassman
Angiogenesis
Orphan Drug Designation

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Jonathan Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh
Read the transcript here.

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions

20 episodes